such as tricor u2122 fenofibrate from abbott laboratories inc north chicago ill ppar gamma agonists selected from a group consisting of rosiglitazaone glaxo smith kline and pioglitazone takeda hmg coa reductase inhibitors selected from a group consisting of lovastatin atorvastatin simvastatin pravastatin cerivastatin and fluvastatin endothelin receptor antagonists such as abt 627 having general formula c 29 h 38 n 2 o 6 clh and the following structural formula from abbott laboratories inc north chicago ill matrix metalloproteinase inhibitors such as abt 518 having general formula c 21 h 22 f 3 no 8 s and having the following structural formula from abbott laboratories inc north chicago ill antiallergic agents such as permirolast potassium nitroprusside phosphodiesterase inhibitors prostaglandin inhibitors suramin serotonin blockers steroids thioprotease inhibitors triazolopyrimidine and nitric oxide while the foregoing beneficial agents are known for their preventive and treatment properties the substances or agents are provided by way of example and are not meant to be limiting further other beneficial agents that are currently available or may be developed are equally applicable for use with the present invention if desired or necessary the beneficial agent can include a binder to carry load or allow sustained release of an agent such as.